Navigation Links
Wyeth Announces Executive Change in Finance Organization
Date:2/28/2008

-- John C. Kelly Named New Controller --

MADISON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced the promotion of John C. Kelly to Vice President and Controller, Wyeth, effective March 28, 2008. Mr. Kelly replaces Paul J. Jones, who is retiring after a 30-year career at Wyeth, including serving as Vice President and Controller for the past 13 years.

Since joining Wyeth in 2002, Mr. Kelly has handled a wide range of assignments in finance, most recently as Vice President, Finance Operations. Prior to joining Wyeth, he was at Arthur Andersen LLP for more than 35 years where he served as a Partner in the firm, the Partner in Charge of the Audit & Business Consulting Practice of Metro New York, and Managing Partner and Head of Accounting & Audit Practice for the firm's New Jersey-based operations. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. He earned both his B.S. in business administration and M.B.A. in international finance from Seton Hall University.

"Since joining Wyeth, John has had a significant impact on our Company," says Greg Norden, Senior Vice President and Chief Financial Officer, Wyeth. "He has contributed much to the success of Wyeth and the finance organization during the past six years."

Mr. Jones joined Wyeth in 1977 after eight years at Arthur Andersen LLP. While at Wyeth, he served in a broad range of leadership positions in the finance organization, including Chief Financial Officer of the Company's international and U.S. pharmaceutical businesses.

"Paul has had a highly productive career and brought his broad-based financial and deep technical knowledge to every position he has held at Wyeth," says Mr. Norden. "He has made exceptional contributions to the development of the Company as we know it today and has been an invaluable part of the finance team during his tenure."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):